Hematologic Oncology

Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.

Pegylated G-CSF produced rates of successful CD34-positive cell collection and safety comparable to daily G-CSF in healthy allogeneic transplant donors.

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

E. Anders Kolb, MD, breaks down a new way to measure how blood cancer treatment advances translate into years of life saved.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.

Hagop M. Kantarjian, MD, discusses 5-year OPTIC trial data supporting a response-based, dose-reduction strategy for ponatinib in chronic-phase CML.

The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.

Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia, according to data from OPTIC.

Uma Borate, MBBS, discusses reducing treatment toxicity in older patients with AML and the potential for time-limited therapy strategies.

Uma Borate, MBBS, MS, discusses results of the OPTI-AML trial comparing 14- and 28-day venetoclax dosing in older adults with acute myeloid leukemia.

Daniel Morillo, MD, discusses future research directions for golcadomide in relapsed/refractory follicular lymphoma.

Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.

Andrew Evens, DO, MBA, MSc, SVP, & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across New Jersey.

Daniel Morillo, MD, discusses AEs associated with golcadomide plus rituximab in relapsed/refractory follicular lymphoma.

Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

A rituximab biosimilar has been approved by the FDA.

Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.